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Abstract
Background: The proteasome inhibitor bortezomib can inhibit activation of the transcription
factor NF-κB, a mechanism implicated in its anti-neoplastic effects observe d  i n  m a n t l e  c e l l
lymphoma (MCL). However, NF-κB can be activated through many distinct mechanisms, including
proteasome independent pathways. While MCL cells have been shown to harbor constitutive NF-
κB activity, what fraction of this activity in primary MCL samples is sensitive or resistant to
inhibition by bortezomib remains unclear.
Results: Proteasome activity in the EBV-negative MCL cell lines Jeko-1 and Rec-1 is inhibited by
greater than 80% after exposure to 20 nM bortezomib for 4 hours. This treatment decreased NF-
κB activity in Jeko-1 cells, but failed to do so in Rec-1 cells when assessed by electrophoretic
mobility shift assay (EMSA). Concurrently, Rec-1 cells were more resistant to the cytotoxic effects
of bortezomib than Jeko-1 cells. Consistent with a proteasome inhibitor resistant pathway of
activation described in mouse B-lymphoma cells (WEHI231) and a breast carcinoma cell line (MDA-
MB-468), the bortezomib-resistant NF-κB activity in Rec-1 cells is inhibited by calcium chelators,
calmodulin inhibitors, and perillyl alcohol, a monoterpene capable of blocking L-type calcium
channels. Importantly, the combination of perillyl alcohol and bortezomib is synergistic in eliciting
Rec-1 cell cytotoxicity. The relevance of these results is illuminated by the additional finding that a
considerable fraction of primary MCL samples (8 out of 10) displayed bortezomib-resistant
constitutive NF-κB activity.
Conclusion: Our findings show that bortezomib-resistant NF-κB activity is frequently observed
in MCL samples and suggest that this activity may be relevant to MCL biology as well as serve as a
potential therapeutic target.
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Background
Mantle cell lymphoma (MCL) is an aggressive B-cell non-
Hodgkin lymphoma genetically characterized by the
t(11;14)(q13;q32) translocation with overexpression of
cyclin D1. [1] It typically presents as advanced disease in
men over 60 years of age and accounts for approximately
5% of all non-Hodgkin lymphoma (NHL) with an inci-
dence of approximately 3,000 cases per year in the United
States [2-5]. MCL remains a therapeutic challenge, having
the worst 5-year survival of any lymphoma subtype in the
NHL classification project and a median survival of only 3
or 4 years [6-15].
The need for new treatment strategies has led to the devel-
opment of a novel class of pharmacologic agents, the pro-
teasome inhibitors. After demonstrating activity in
patients with refractory multiple myeloma with a manage-
able toxicity profile, bortezomib (Velcade; Millenium
Pharmaceuticals Inc, Cambridge, MA), a reversible inhib-
itor of chymotryptic-like activity in the 26S proteasome,
was the first agent of this class to be approved for clinical
use [16-20]. When administered as a single agent in
relapsed MCL, response rates of 29–48% have been dem-
onstrated [21-24]. The efficacy of bortezomib in treating
previously refractory cases of MCL is believed to involve
multiple signaling pathways, and among them, the
nuclear factor κB (NF-κB) pathways [25-27].
NF-κB is a family of related transcription factors including
NF-κB1 (p50 and its precursor p105), NF-κB2 (p52 and
its precursor p100), p65 (RelA), RelB, and cRel that are
typically found as homo- or heterodimers. This family of
transcription factors is unique in its capacity to coordinate
transcription of a diverse array of genes, including those
involved in cell proliferation and resistance to apoptosis,
thereby opening avenues for malignant cell growth [28-
31]. NF-κB has been implicated as an important mediator
of malignant cell growth and survival in MCL. While most
non-malignant cells contain inactive NF-κB complexes
sequestered in their cytoplasm, constitutive activation of
NF-κB has been frequently observed in both MCL cell
lines and primary MCL samples and accordingly, inhibi-
tion of this constitutive activation has been shown to elicit
cell cycle arrest and cell death [25,26,32,33].
There are multiple distinct signaling pathways that lead to
activation of NF-κB. The best characterized mechanisms
of inducible NF-κB activation are termed "canonical" and
"non-canonical". The canonical pathway is initiated
through receptor binding by ligands such as tumor necro-
sis factor alpha or lipopolysaccharide. This activates a sig-
naling cascade involving the phosphorylation of the NF-
κB inhibitor, IκBα, by the IκB kinase (IKK) complex, fol-
lowed by its ubiquitination and subsequent degradation
by the 26S proteasome. Degradation of IκBα allows NF-
κB to translocate to the nucleus where it can regulate tran-
scription [29,34]. Alternatively, the non-canonical path-
way is activated by ligands such as B-cell activating factor
family or lymphotoxin beta leading to the NF-κB inducing
kinase (NIK) and IKK alpha (IKKα) facilitated, proteas-
ome-mediated, conversion of p100 to its active form, p52
[35-37]. This ultimately results in selective activation of
the p52/RelB complex and activation of its target gene.
There are also other mechanisms of NF-κB activation
including those that involve the calpain family of cal-
cium-dependent proteases [38-40], hypoxia-reoxygena-
tion-induced tyrosine phosphorylation of IκBα that leads
to its dissociation from NF-κB without degradation [41],
ultraviolet irradiation induced phosphorylation of IκBα
via casein kinase II leading to its degradation and NF-κB
activation [42], and a pathway referred to as PIR (proteas-
ome inhibitor resistant) that involves degradation of IκBα
in a manner independent of proteasomes but dependent
on calcium, calmodulin, and L-type calcium channels [43-
46]. Thus, depending on physiologic and pathologic set-
tings, different NF-κB activation mechanisms could be
involved, some sensitive to proteasome inhibitors while
others not.
While inducible pathways of NF-κB activation are better
characterized, less is known about the mechanisms of
constitutive NF-κB activation. In addition to MCL, consti-
tutive NF-κB activity has also been demonstrated in other
malignancies including, adult T-cell leukemia, diffuse
large B-cell lymphoma, multiple myeloma, Reed-Stern-
berg cells of Hodgkin lymphoma, pancreatic adenocarci-
noma, prostate adenocarcinoma, squamous cell
carcinoma of the head and neck, and breast carcinoma
[47-53]. Recent studies examining multiple myeloma
samples have demonstrated that ~20% of patient samples
harbor mutations or amplifications of genes whose pro-
tein products participate in either canonical or non-
canonical NF-κB signaling pathways, leading to constitu-
tive NF-κB activation [54,55]. Among the many different
NF-κB activation mechanisms, the PIR pathway has been
found constitutively active in a variety of cell lines ana-
lyzed, including the WEHI231 and other murine B-cell
lymphoma lines, during in vitro differentiation of a v-Abl
transformed pre-B cell line, the MDA-MB 468 human
breast cancer cell line, and the RPMI8226 human multiple
myeloma cell line [43-46,56-59]. Importantly, the PIR
pathway for constitutive NF-κB activation has been shown
to be highly resistant to over 10 different types of protea-
some inhibitors analyzed, including bortezomib, but
selectively sensitive to inhibition by perillyl alcohol
(POH), a monoterpene with anticancer activity which
can, among other activities, block L-type calcium channels
[45,46,58,60]. It is as yet unknown whether MCL harbors
PIR constitutive NF-κB activity.Molecular Cancer 2008, 7:40 http://www.molecular-cancer.com/content/7/1/40
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Herein, we show that Rec-1 cells have constitutive PIR NF-
κB activation and they are more bortezomib-resistant rel-
ative to Jeko-1 cells which lack PIR activation. Inhibiting
PIR NF-κB activity with POH is synergistic with borte-
zomib in inducing Rec-1 cell death. Moreover, eight of ten
primary MCL samples analyzed demonstrated constitu-
tive NF-κB activity with high resistance to bortezomib.
Overall, we show that bortezomib-resistant constitutive
NF-κB activity is frequently observed in primary MCL
samples, suggesting that nonproteasome-dependent
mechanisms, including the PIR pathway, may be relevant
to MCL biology.
Materials and methods
Cell lines, antibodies, and chemicals
Two well-characterized Epstein-Barr virus-negative
human MCL cell lines, Jeko-1 and Rec-1 [61] were cul-
tured in RPMI 1640 (Mediatech Inc, Herndon, VA) sup-
plemented with 10% fetal bovine serum (HyClone
Laboratory, Logan, UT), 1250 U of penicillin G (Sigma-
Aldrich, St. Louis, MO), 0.5 mg of streptomycin sulfate
(Sigma), and 0.1% Basal Medium Eagle amino acid sup-
plement in 37°C incubators with 5% CO2. p65 (C20) and
RelB (C19) antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA), p50 (06–886) and p52/
p100 (06–413) antibodies were purchased from Upstate
Biotechnologies (Lake Placid, NY), and the cRel (SA-172)
antibody was purchased from Biomol (Plymouth Meet-
ing, PA). Bortezomib was commercially obtained from
Millenium Pharmaceuticals, Inc. (Cambridge, MA) for
experimental purposes. Propiduim iodide (PI) was pur-
chased from Sigma-Aldrich (St. Louis, MO) and Aldrich
Chemical Company (Milwaukee, WI) supplied the per-
illyl alcohol (POH). BAPTA/AM [bis-(o-aminophe-
noxy)ethane-N, N, N', N'-tetra-acetic acid tetrakis-
(acetoxymethyl ester)], EGTA/AM [ethylene glycol tetra-
acetic acid tetrakis-(acetoxymethyl ester)], W12 [N-(4-
aminobutyl)-1-naphthalenesulphonamide], and W13 [N-
(4-aminobutyl)-5-chloro-1-naphthalenesulphonamide]
were purchased from Calbiochem (San Diego, CA).
Electrophoretic mobility shift assay (EMSA)
For MCL cell lines, approximately 1.0 × 106 cells/mL were
allowed to rest for 2–4 hours in a 5% CO2 incubator at
37°C. Cells were then treated with the appropriate chem-
icals and spun down at 13,000 × g in a benchtop Eppen-
dorf centrifuge for 10 seconds. Pellets were washed once
in 1× phosphate buffered saline (PBS), spun down again
at 13,000 × g in a benchtop Eppendorf centrifuge for 10
seconds, and stored at -70°C. Cell pellets were lysed in
totex buffer (20 mM HEPES [pH 7.9], 350 mM NaCl, 20%
glycerol, 1% NP-40, 1 mM MgCl2, 0.5 mM EDTA, 0.1 mM
EGTA, 0.5 mM DTT, 0.5 mM PMSF, 1 ug/mL aprotinin),
spun down at 13,000 × g in an Eppendorf centrifuge for
10 minutes at 4°C to remove cell debris, and the superna-
tant subjected to the assay as described previously [62],
except for the use of a mini-EMSA tailored for the limited
protein extracts from the primary MCL samples. Here, 6
μL of reaction was set up and 5 μL of each reaction mix
was loaded onto 10 mm × 3 mm × 1 mm wells. The Igκ-
κB oligonucleotide probe was as described previously
[62]. For supershift assays, the indicated antibodies were
added to each reaction prior to the addition of the Igκ-κB
probe. Gels were dried and exposed on Phosphor Screens
(Amersham Biosciences, Piscattaway, NJ) followed by
quantitation of NF-κB DNA-binding through Image-
Quant analysis (GE Healthcare, Piscattaway, NJ). Fold
intensity for each lane was normalized to Oct-1 values
from the same sample and then to the vehicle treated con-
trol values at the indicated time point.
For primary MCL samples, the equivalent of one half of
the protein from 5.0 × 104 cells from the Z138 MCL cell
line was loaded in each well of the mini-EMSA. In order
to correct for differences in amounts of protein between
each lane in a gel, fold intensity for each lane was normal-
ized to Oct-1 values from the same sample and then to the
vehicle treated control value. Additionally, one half of
total protein from 5.0 × 104 Z138 cells was run in parallel
with every patient sample to serve as an internal standard
in order to facilitate comparison of relative constitutive
NF-κB activities between each of the MCL patient sam-
ples. To this end, densitometry values of primary MCL
samples were additionally normalized to the internal
standard Z138 value.
Apoptosis assays
PI staining was used to examine cell death in non-fixed
cells by flow cytometric analysis. 30 ug/mL of PI was
added to the cells 5 minutes prior to data collection on a
FACSCalibur flow cytometer (Becton Dickinson Bio-
science, San Jose, CA) followed by analysis on Cell Quest
software (Becton Dickinson Bioscience) [63].
26S proteasome activity assay
A live-cell luminogenic substrate based assay of the chy-
motrypsin-like activity of the 26S proteasome was used
according to the manufacturer's instructions (Proteas-
ome-Glo Assay with Suc-LLVY-Glo substrate, Promega
Corporation, Madson, WI). Luminescence was recorded
on a plate-reading luminometer (PerkinElmer, Waltham,
MA).
Drug combination evaluation
The cytotoxic effect of combined bortezomib and POH on
MCL cell lines was determined by the combination index
(CI) method, based on the median-effect principle
derived by Chou and Talalay [64,65], and analyzed by the
Calcusyn computer program (Biosoft, Cambridge, UK).
Briefly, median-effect analysis is a measure of synergismMolecular Cancer 2008, 7:40 http://www.molecular-cancer.com/content/7/1/40
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or antagonism where the median-effect equation corre-
lates the drug dose with cytotoxic effect in the equation: fa/
fu = (D/Dm)m in which D is the dose of the drug; Dm is the
median-effect dose signifying the potency, determined
from the x-intercept of the median-effect plot; fa is the frac-
tion affected by the dose; fu is the fraction unaffected; and
m is an exponent that signifies the sigmoidocity of the
dose-effect curve. CI is then calculated: CI = (D)1/(Dx)1 +
(D)2/(Dx)2, where (D)1 and (D)2 are the doses of drug 1
and drug 2 that have x effect when used in combination
and (Dx)1 and (Dx)2 are the doses of drug 1 and drug 2 that
have the same x effect when used alone. Synergy is present
when the CI is less than 1.0. The combination is additive
when CI equals 1.0, and is antagonistic when greater than
1.0.
Primary MCL samples
Twenty samples of fresh bone marrow, peripheral blood,
or lymph node (Table 1) were obtained from patients
diagnosed with MCL according to World Health Organi-
zation criteria [1] either at the time of initial diagnosis or
disease recurrence. The specimens were cryopreserved in a
solution containing 20% DMSO in RPMI media with 10%
fetal calf serum after enrichment of mononuclear cells by
density gradient separation and stored at -140°C. At the
time of analysis, specimens were thawed and anti-CD19
magnetic microbeads were used to positively select cells
through the MACS cell sorting system following the man-
ufacturer's protocol (Miltenyi Biotec, Auburn, CA). From
the 20 cases, 10 that had greater than 60% lymphocytes
that co-expressed CD5 with CD19 and had greater than
5.0 × 105 cells for EMSA analysis were included. In these
10 cases, the mean percentage of lymphocytes demon-
strating the MCL phenotype with combined expression of
CD5 and CD19 was 78% (range 62% to 96%) as analyzed
on a FACSCalibur flow cytometer (Becton Dickinson,
Franklin Lakes, NJ) with anti-CD5-PE and anti-CD19-
PECy5 antibodies (BD Biosciences, San Jose, CA) (Table
1). The primary cells were cultured in media identical to
that used for the MCL cell lines.
Results
Constitutive NF-κB activation in two MCL cell lines is 
associated with distinct NF-κB heterodimers and 
mechanisms
Constitutive activation of NF-κB has been implicated as a
critical modulator of malignant cell growth and survival
in a number of human malignancies including MCL
[25,47-53]. To avoid complications arising from the latent
membrane protein 1 of EBV, which has been shown to
activate NF-κB [66], we first investigated constitutive NF-
κB complexes in the EBV-negative MCL cell lines, Jeko-1
and Rec-1, using EMSA. Both cell lines demonstrated con-
stitutive NF-κB activation with Rec-1 cells having rela-
tively more activity than Jeko-1 cells (Figure 1A).
Supershift analysis showed that Jeko-1 and Rec-1 cells
contain both p50/p65 and p50/cRel heterodimers, with
Rec-1 having relatively more p50/cRel (Figure 1B). NF-κB
p50/p65 and p50/cRel heterodimers can be activated via
both canonical, PIR, and other pathways [34,44,45], sug-
gesting that distinct mechanisms mediating constitutive
NF-κB activation may exist in these MCL cell lines.
We next investigated whether a proteasome inhibitor
resistant activation pathway was involved in maintaining
constitutive NF-κB activity in Jeko-1 and Rec-1 cells. To
evaluate the efficacy of inhibition of the chymotryptic-like
proteasomal activity in these cells by bortezomib, a live-
cell luminogenic substrate based assay was used (see
Materials and Methods). Both cell lines showed marked
inhibition of proteasomal activity following treatment
with bortezomib. Exposure of these cells to 20 nM of bort-
ezomib for four hours decreased proteasome activity to
less than 20% of vehicle treated controls (Figure 2A).
Next, we evaluated the effect of proteasome inhibition on
constitutive NF-κB activity. NF-κB activity was decreased
in Jeko-1 cells but not in Rec-1 cells after 4 hour treatment
with either 20 nM bortezomib (Figure 2B) or 100 nM of
bortezomib (data not shown). The bortezomib-resistance
of constitutive p50/p65 and p50/c-Rel activity in Rec-1
Table 1: Characteristics of MCL patient samples.
Patient no. Age (years) Gender Source Disease status Morphologic variant Tumor cells (%)1
1 81 F Bone marrow Primary Blastic 61.6
2 58 F Bone marrow Recurrence Classic 95.6
3 77 F Peripheral blood Primary Blastic 74.8
4 75 F Bone marrow Primary Blastic 71.1
5 56 F Lymph node Primary Classic 83.0
6 53 F Lymph node Recurrence Classic 88.6
7 49 M Peripheral blood Primary Classic 96.1
8 57 F Bone marrow Primary Classic 83.6
9 62 M Bone marrow Recurrence Classic 76.8
10 67 M Bone marrow Primary Classic 69.7
1 Percentage of cells co-expressing CD5 and CD19 after CD19 positive cell selection.Molecular Cancer 2008, 7:40 http://www.molecular-cancer.com/content/7/1/40
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cells could be due to the involvement of the PIR pathway.
To determine if this is the case, we treated Rec-1 cells with
agents known to block the PIR pathway, including cal-
cium chelators (BAPTA/AM and EGTA/AM), calmodulin
inhibitors (W12 and W13) and the anticancer agent, POH
[43-46]. As shown in Figure 2C and 3C, these agents effec-
tively blocked constitutive NF-κB activity in this cell line,
thereby suggesting the involvement of the PIR pathway.
Synergism of POH with bortezomib in a MCL cell line 
harboring bortezomib-resistant constitutive NF-κB activity
Because NF-κB has been shown to mediate cellular growth
and survival in MCL [25], we evaluated whether cells pos-
sessing bortezomib-resistant constitutive NF-κB activity
would in fact demonstrate a survival advantage in the face
of bortezomib treatment. PI staining was used to assess
the cytotoxic effect of 24 hour treatment with 20 nM bort-
ezomib on the MCL cell lines. This method enables enu-
meration of both apoptotic and necrotic non-fixed cells
by flow cytometric analysis (Figure 3A) [46,63]. Jeko-1 
Constitutive NF-κB activation in MCL cell lines Figure 1
Constitutive NF-κB activation in MCL cell lines. (A) Electrophoretic mobility shift assay (EMSA) of whole cell extracts 
from 1.0 × 106 cells of EBV-negative MCL cell lines probed with 32P-radiolabeled oligonucleotide containing the consensus NF-
κB binding sequence. Oct-1 binding is shown as a loading control. Assignment of the NF-κB complexes are based on supershift 
analysis shown in (B). (B) Supershift EMSA of whole cell extracts from MCL cell lines.
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Bortezomib-resistant constitutive NF-κB activity in Rec-1 cells Figure 2
Bortezomib-resistant constitutive NF-κB activity in Rec-1 cells. (A) Chymotrypsin-like activity of the 26S proteasome in cell lines after exposure 
to increasing doses of bortezomib for 4 hours was assessed by luminescence generated by substrate cleavage (Proteasome-Glo Assay, Promega Corpora-
tion, Madison, WI). Results (mean ± 1SD from triplicate wells) are shown as a percent of luminescence relative to vehicle treated controls. (B) EMSAs of 
MCL cell lines treated with 20 nM bortezomib for 1 to 4 hours probed with 32P-radiolabeled oligonucleotide containing either the consensus NF-κB or 
Oct-1 binding sequence. Fold intensity was calculated by ImageQuant analysis of Phosphor Screens normalized to Oct-1 values from the same sample and 
then to the vehicle treated control values at the indicated time point. Gels shown are representative of one of three independent experiments. (C) EMSA 
of Rec-1 cells at time zero (0T) and treated with 0.1% DMSO (DMSO) for 3 hours, the calcium chelators BAPTA/AM (60 μM) and EGTA/AM (60 μM) for 
3 hours, or the calmodulin inhibitors W12 (40 μM) and W13 (10 μM) for 3 hours. Fold activity refers to NF-κB binding normalized to Oct-1 binding in 
each condition. Gel shown is representative of 3 independent experiments.
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cells were sensitive to bortezomib induced cytotoxicity
and Rec-1 cells were significantly less so with 47 ± 6.2%
and 82 ± 5.1% viability respectively, relative to vehicle
treated controls (Figure 3B).
To determine if inhibition of the PIR NF-κB activity with
POH would induce bortezomib sensitization, we next
evaluated synergy between bortezomib and POH in the
Rec-1 cells. We also treated Jeko-1 cells as a negative con-
trol since constitutive NF-κB activity in this cell line dem-
onstrated high sensitivity to bortezomib but not to POH
(Figure 3C). To accurately compare the effect of POH on
NF-κB activity in Jeko-1 and Rec-1 cells, we first deter-
mined the potency of POH in each cell line by assessing
cytotoxicity through PI staining followed by flow cytomet-
ric quantification and calculation of the median-effect
dose (Dm) for each cell line (see methods). We found that
POH was more potent in Rec-1 (Dm = 0.32 mM) than
Jeko-1 (Dm = 0.67 mM) cells (Figure 4A). These anti-MCL
doses are similar in range to those seen against other can-
cer types [67-70]. When treated with their respective Dm of
POH for 4 hours, NF-κB activity was reduced in Rec-1 but
not Jeko-1 cells (Figure 3C). When Rec-1 cells were treated
with a fixed ratio of bortezomib and POH, analysis for
synergy by the method of Chou-Talalay showed combina-
tion indices (CI) of 0.83 and 0.74 at ED75 and ED90,
respectively (Figure 4B). These CI values are <1.0, indicat-
ing synergistic toxicity with POH and bortezomib. In con-
trast, parallel synergy experiments in Jeko-1 cells
demonstrated CIs of 1.13 and 1.03 at ED75 and ED90,
respectively (Figure 4B), suggesting not only a lack of syn-
ergy, but even a modest antagonism. These findings show
that inhibition of constitutive PIR NF-κB activity in Rec-1
cells by POH induces synergistic toxicity with bortezomib.
Cytotoxic effect of bortezomib and POH on MCL cell lines Figure 3
Cytotoxic effect of bortezomib and POH on MCL cell lines. (A) Assessment of viability by staining non-fixed Rec-1 
cells with PI (30 μg/mL) followed by flow cytometric analysis showing populations of (a) live cells, (b) necrotic cells, and (c) 
apoptotic cells. (B) Viability of Rec-1 and Jeko-1 cells treated with either 20 nM bortezomib or 0.3 mM POH for 24 hours rel-
ative to controls exposed only to vehicle shown as mean ± 1SD from triplicate wells. The unpaired t-test between viability of 
Jeko-1 and Rec-1 cells treated with bortezomib * p = 0.002 or POH **p = 0.0001 were both statistically significant (p < 0.01). 
(C) EMSAs of whole cell extracts from 1.0 × 106 cells treated with 20 nM bortezomib or their respective median-effect dose of 
POH for 4 hours probed with 32P-radiolabeled oligonucleotide containing either the consensus NF-κB or Oct-1 binding 
sequence. Fold activity refers to NF-κB binding normalized to Oct-1 binding in each condition.
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This synergy is not seen in Jeko-1 cells that harbor consti-
tutive NF-κB activity utilizing the proteasome-dependent
canonical pathway.
Bortezomib-resistant constitutive NF-κB activity is 
frequently observed in primary MCL samples
Since the number of primary MCL cells in patient-derived
samples is very limited in general, we next developed a
scaled down version of the traditional EMSA assay ("mini-
EMSA") (see methods). In order to validate the precision
of this assay, assessment of NF-κB band intensities of 5
replicate samples calculated by ImageQuant analysis of
Phosphor Screens exposed to the dried mini-EMSAs
loaded with half the protein extracts from 2.5 and 5.0 ×
104 cells from the Z138 MCL cell line was performed. The
other half samples were used for the loading control Oct-
1 binding. The coefficient of variation of this assay for 5.0
× 104 Z138 cells was of 5.9% (Figure 5A and 5B). While
cell numbers greater than 5.0 × 104 produced reproduci-
ble results, when cell numbers were reduced below this
number, the reproducibility suffered greatly. Thus, we
used 5.0 × 104 Z138 cell equivalents as the target amount
of protein from patient samples to load in each gel. We
also ran Z138 cell samples as a standard in each EMSA so
that we could compare results between primary samples
run on different days in spite of day to day variances of the
specific activity of the Igκ-κB probe (Figure 5D). Constitu-
tive NF-κB activity was present in all primary samples and
ranged in intensity from 0.16 to 3.45 fold of the Z138
standard cells (Figure 5E).
Next, we investigated the sensitivity of constitutive NF-κB
activity in primary MCL samples to treatment with 20 nM
or 100 nM of bortezomib for four hours. The degree of 
POH synergizes with bortezomib in inducing cytotoxicity in Rec-1, but not Jeko-1 cells Figure 4
POH synergizes with bortezomib in inducing cytotoxicity in Rec-1, but not Jeko-1 cells. (A) Viability assessed by PI 
staining with flow cytometric quantitation relative to controls exposed only to vehicle at various doses of bortezomib, POH, or 
combination of both for 24 hours. Results expressed as mean ± 1SD of triplicate wells. (B) Combination index (CI) plots gen-
erated by the computer software CalcuSyn (Biosoft, Cambridge, UK) according to the Chou-Talalay equation ("Materials and 
Methods") from cytotoxicity data shown in (A). Effect is equivalent to cytotoxicity where effect of 1.0 = 100% relative cytotox-
icity. Synergy is present when CI < 1.0. The combination is additive when CI = 1.0, and antagonistic when CI > 1.0.
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Bortezomib-resistant constitutive NF-κB activity in MCL patient samples Figure 5
Bortezomib-resistant constitutive NF-κB activity in MCL patient samples. (A) Mini-EMSA performed on one half of the protein extracts from 
2.5 × 104 and 5.0 × 104 Z138 cells probed with 32P-radiolabeled oligonucleotide containing the consensus NF-κB sequence. (B) Mean ± 1SD of densitomet-
ric values in relative units (RU) from ImageQuant analysis of Phosphor Screens exposed to mini-EMSA from (A). *Coefficient of variation (CV) = 20.9% 
**CV = 5.9% (C) Chymotrypsin-like activity of the 26S proteasome in 2 patient samples after exposure to increasing doses of bortezomib for 4 hours as 
assessed by luminescence generated by substrate cleavage (Proteasome-Glo Assay, Promega Corporation, Madison, WI). Results are shown as percent of 
luminescence relative to a vehicle treated control in a single experiment. (D) Mini-EMSA of anti-CD19 magnetic microbead selected cells from MCL 
patient samples treated with 20 nM and 100 nM of bortezomib for 4 hours. Z represents a standard composed of 5.0 × 104 Z138 cells run with each 
patient sample as an internal control. The protein extract from this standard was halved, with each half run alongside corresponding halved patient sam-
ples, where one half was probed with oligonucleotide containing the NF-κB consensus binding sequence and the other half probed with oligonucleotide 
containing the Oct-1 consensus binding sequence. (E) NF-κB DNA-binding of MCL patient samples corrected for Oct-1 intensity then normalized to their 
respective vehicle treated control and finally normalized to Z138 internal control for MCL patient samples processed and analyzed as described in (D). (F) 
NF-κB DNA-binding of MCL patient 6 after treatment with 1.0 mM POH for 4 hours relative to vehicle treated control, corrected for Oct-1 intensity.
NF-κB
Fold:
1.0
0.9
1.0
1.0
0.9
0
20
40
60
80
100
02 0 4 0 6 0 80 100
Bortezomib (nM)
Patient 6
Patient 7
R
e
l
a
t
i
v
e
 
p
r
o
t
e
a
s
o
m
e
 
a
c
t
i
v
i
t
y
 
(
%
)
 
1.4
1.1
1.0
0.9
0.8
5.0 x 10 2.5 x 10
4 4
Free
probe
0
1
2
3
2.5 x 10
N
F
-
κ
B
 
b
a
n
d
 
i
n
t
e
n
s
i
t
y
 
(
R
U
)
4 4 5.0 x 10
*
**
Bortezomib (nM):
NF-κB
Oct-1
Fold : 1.0
1.5
1.4
Patient 8
Free probe
0 20100 Z
Patient 2
1.0
1.0
0.7
Patient 6
1.0
1.2
0.8
0
1.0
2.0
3.0
4.0
1 2 34567 89 10
Patient
Constitutive activity 20nM bortezomib 100nM bortezomib 
N
F
-
k
B
 
/
 
O
c
t
-
1
 
d
i
v
i
d
e
d
 
b
y
Patient 6
0 20100 Z 0 20100 Z
 
Z
1
3
8
 
N
F
-
κ
B
 
/
 
O
c
t
-
1
A. B. C.
D.
E.
100
80
60
40
20
0
Control 
POH 
F.
R
e
l
a
t
i
v
e
 
N
F
-
κ
B
 
 
 
a
c
t
i
v
i
t
y
 
(
%
)Molecular Cancer 2008, 7:40 http://www.molecular-cancer.com/content/7/1/40
Page 10 of 14
(page number not for citation purposes)
proteasome inhibition achieved at these dosages in two
representative patients (patient 6 and patient 7) was com-
parable to that seen in the MCL cell lines tested by the
same assay (Figure 5C). Relative to vehicle treated con-
trols, only two patients (patient 4 and patient 9) demon-
strated a 50% or greater decrease of NF-κB DNA-binding
after treatment by either dose of bortezomib (Figure 5E).
Constitutive NF-κB activity in patients 2 and 6 showed a
very modest inhibition with 20 nM bortezomib, but inter-
estingly not at the 100 nM dose. The others did not show
any overt inhibition of NF-κB activity. Some patient sam-
ples (3, 7 and 8) showed modest increases in constitutive
NF-κB activity after treatment of cells with bortezomib.
Significantly, POH treatment of cells from patient 6,
which had the most robust degree of constitutive activity,
resulted in marked inhibition of NF-κB activity (Figure
5F). These results reveal that constitutive NF-κB activity
present in a considerable fraction of primary MCL cases is
refractory to inhibition by high dose bortezomib treat-
ment. Moreover, this resistance is at least in part due to the
involvement of the PIR pathway in MCL samples.
Discussion
Under normal circumstances, the NF-κB signaling path-
way is tightly controlled and plays important roles in lym-
phocyte development and the immune response;
however, dysregulation of this pathway can lead to its
constitutive activation in cancer cells. Although the pro-
teasome inhibitor bortezomib can target the constitutive
NF-κB activity maintained by both canonical and non-
canonical pathways, proteasome inhibitor resistant mech-
anisms of NF-κB activation have been identified and one
of them in particular, the PIR pathway, is constitutively
activated in several cancer cell lines [43-46,56-58]. The
PIR pathway may provide cancer cells a mechanism of
maintaining constitutive NF-κB activation in the face of
proteasome inhibition and confer a degree of relative
resistance to proteasome inhibitor induced cytotoxicity.
In turn, assessing the prevalence of bortezomib-resistant
constitutive NF-κB activity in MCL patient samples illumi-
nates whether proteasome inhibition can efficiently abro-
gate constitutive NF-κB activity MCL patients. Here, we
found that bortezomib failed to decrease NF-κB activity
by more that 50% in eight of ten primary patient samples,
despite treatment with doses that elicited greater than
80% proteasome inhibition, which is the clinical target
with this drug. These results demonstrate a surprising
finding that constitutive NF-κB activity in primary MCL
cells is often resistant to bortezomib exposure, at least in
vitro.
We evaluated the EBV-negative Jeko-1 and Rec-1 cell lines
to eliminate the effect of NF-κB activation by latent mem-
brane protein 1, which would work via the canonical
pathway [66]. Dosages of bortezomib chosen were reflec-
tive of pharmacokinetic studies where patients on stand-
ard bortezomib dosing regimens of 1.0 mg/m2  had
estimated peak plasma concentrations of approximately
200 nM that rapidly decreased and plateaued at approxi-
mately 5 nM in less than 5 hours, and concordantly, peak
inhibition of proteasome activity in whole blood lysates
reached approximately 75%, falling off to approximately
35% after 24 hours [71-73]. As such, in the MCL cell lines,
we used a 20 nM dose of bortezomib for 4 hours that pro-
duced at least 80% proteasome inhibition to reflect maxi-
mal proteasome inhibition achievable with a reasonably
attainable plasma bortezomib concentration. In primary
MCL samples, because we could not assess the effect of
bortezomib on proteasome activity in each case due to
limitation of MCL cell number, we treated samples with
both 20 nM and 100 nM bortezomib when determining
its effect on NF-κB activation to ensure that sufficient pro-
teasome inhibition was attained.
Constitutive NF-κB activity was present in both Jeko-1
and Rec-1 cells. Jeko-1 cells appeared to constitutively
activate NF-κB through the canonical pathway as evi-
denced by the presence of largely p50/p65 heterodimers
and inhibition of constitutive NF-κB activity by borte-
zomib. In contrast, Rec-1 cells appeared to activate NF-κB
through the PIR pathway, where despite proteasome inhi-
bition by bortezomib, DNA-binding by largely p50/cRel
heterodimers was not inhibited; similar to our observa-
tions in the WEHI231 murine B-cell lymphoma cell line
which displays a high-level of proteasome inhibitor resist-
ant constitutive NF-κB activity [43-46,56-58]. This activity
was nevertheless sensitive to inhibition by calcium chela-
tors, calmodulin inhibitors, and POH, agents that block
the PIR pathway but do not generally block canonical or
non-canonical pathways.
POH is a monoterpene derived from plant essential oils
that has been shown to have significant antitumor activity
against multiple cancer models. [60,67-70] Its mecha-
nism of action includes inhibition of G-protein prenyla-
tion [74,75] and alterations in cell cycle genes with
decreased cyclin D1 [76,77]. Of interest, POH has also
been shown to inhibit the L-type calcium channels impor-
tant for the maintenance of PIR constitutive NF-κB activity
in both WEHI231 lymphoma cells and MDA-MB-468
breast cancer cells [46]. Indeed, in Rec-1 cells, POH treat-
ment conferred a marked decrease in constitutive NF-κB
activity and correspondingly induced cytotoxicity. In con-
trast, in Jeko-1 cells that harbor constitutive NF-κB activa-
tion maintained by the canonical pathway, POH did not
decreased NF-κB activity and were more resistant to POH
relative to Rec-1 cells. Moreover, POH synergistically
caused toxicity in Rec-1 cells, but not in Jeko-1 cells. These
results demonstrated a parallelism between bortezomib
versus POH sensitivity to canonical versus PIR constitu-Molecular Cancer 2008, 7:40 http://www.molecular-cancer.com/content/7/1/40
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tive NF-κB activation. In MCL cells that harbor constitu-
tive PIR NF-κB activity, POH can synergize with
bortezomib to cause cell death.
It is clearly simplistic to view NF-κB as the sole independ-
ent modulator of MCL or other cancer cell death pheno-
types. Numerous NF-κB-independent mechanisms of
bortezomib-induced apoptosis have been demonstrated
in multiple myeloma, lung cancer cells, and squamous
cell carcinomas. These include the induction of p53,
mouse double minute 2, p21, and p27; phosphorylation
of c-Jun NH(2)-terminal kinase and c-Jun; enhanced AP-1
DNA-binding; and induction of the unfolded protein
response via accumulation of unfolded or misfolded pro-
teins in the endoplasmic reticulum [78-82]. Furthermore,
it has been shown in MCL that a major mode of cell death
induction by bortezomib is through generation of ROS
and Noxa induction that results in activation of the mito-
chondrial apoptotic pathway [27]. It is nevertheless also
well established that NF-κB can confer additional resist-
ance to MCL cells, although it may not be the major deci-
sive factor in controlling the overall sensitivity to
bortezomib. Since the patient samples analyzed herein
did not come from those who have been treated with bort-
ezomib and the sample size was relatively small, the cor-
relation between the presence of proteasome inhibitor
resistant constitutive NF-κB activity in MCL samples and
bortezomib response in patients could not be assessed.
Nevertheless, our data demonstrating synergy between
bortezomib and POH (Figure 4A and 4B) suggest the pos-
sibility that targeting the PIR pathway of constitutive NF-
κB activity with POH (or other anti-PIR agents) could
increase the sensitivity of MCL cells in vivo. This is partic-
ularly relevant, since of the 10 evaluable MCL patient
cases, all demonstrated constitutive NF-κB activation and
only 2 cases showed greater than a 50% inhibition of NF-
κB activity after exposure to bortezomib.
Conclusion
This study demonstrates that constitutive NF-κB activity is
not only present in MCL patient samples, but this activity
is largely resistant to proteasome inhibition by borte-
zomib  in vitro. Additionally, by using Rec-1 cells as a
model of bortezomib-resistant constitutive NF-κB activ-
ity, we showed that blocking this activity with POH was
synergistic with bortezomib in inducing cytotoxicity.
Thus, our data suggests that the full therapeutic potential
of blocking constitutive NF-κB activity as a treatment
strategy for MCL has yet to be fully realized and supports
efforts invested towards the discovery and development of
compounds capable of inhibiting bortezomib-resistant
constitutive NF-κB activity with potency and specificity
superior to POH.
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